Research-use-only tirzepatide and semaglutide: what you are actually buying

The short answer on retatrutide

Retatrutide is an investigational Eli Lilly molecule in Phase 3 trials for obesity, type 2 diabetes and related conditions ^[1]. FDA says it has not been found safe and effective for any condition and cannot be used in compounding ^[2]. That means:

• Switching from tirzepatide to retatrutide: there is no approved protocol, dose or schedule, because there is no approved product. Anything sold as retatrutide outside a clinical trial is an unapproved drug.
• Taking it with Zepbound, Wegovy or Ozempic: no approved guidance exists. The approved labels for tirzepatide and semaglutide already say not to combine them with any other GLP-1 receptor agonist ^{[8] [9]}.
• "Is it better than tirzepatide?" No regulator has reviewed retatrutide data and approved a label, so there is nothing comparable to Zepbound's or Wegovy's label results. A black-market vial is not the drug used in Lilly's trials.

If you are on tirzepatide or semaglutide and want stronger results, talk with your prescriber about the approved options, including dose changes within the label and other approved drugs. See switching GLP-1s for what the labels say.

Is retatrutide the same as Ozempic or tirzepatide?

No. Retatrutide is a separate investigational molecule, not semaglutide (Ozempic, Wegovy) and not tirzepatide (Zepbound, Mounjaro) ^{[1] [2]}. FDA lists it separately from those drugs in its warnings. We have not reviewed retatrutide trial readouts for this page, so we make no claims about how its results compare.

What "research use only" really means

Sellers label peptide vials "research use only" or "not for human consumption," then sell them to consumers. FDA has warned companies selling semaglutide, tirzepatide, retatrutide, survodutide and mazdutide this way, noting they were sold with dosing instructions, and says the products' quality is unknown and may be harmful ^[2]. In its warning letters, FDA has rejected the label when the evidence showed the products were meant for people ^{[10] [11]}. Some sellers use coded names such as "GLP-3 RT" or "GLP1-R" for retatrutide ^{[4] [11]}.

These are not compounded drugs. Compounded semaglutide and tirzepatide come from a licensed pharmacy with a prescription, under rules explained in compounded tirzepatide and compounded semaglutide. Research-use-only vials have neither.

FDA warning letters to research peptide sellers

The companies below are named only because FDA warned them. They are not recommendations, and we do not link to their sites.

FDA warning letters citing research-use GLP-1 products

Letter date (posted)	Recipient	What FDA cited	Letter
Dec 10, 2024 (Dec 17)	Summit Research Peptides	Semaglutide, tirzepatide, retatrutide, cagrilintide, mazdutide labeled "research use only"; FDA found intended human use	FDA letter [10]
Dec 10, 2024 (Dec 17)	Xcel Research LLC	Unapproved GLP-1 products	FDA letter [3]
Dec 10, 2024 (Dec 17)	Swisschems	Unapproved GLP-1 products	FDA letter [3]
Dec 10, 2024 (Dec 17)	Prime Vitality dba Prime Peptides	Unapproved GLP-1 products	FDA letter [3]
March 31, 2026 (April 7)	Prime Sciences	Cagrilintide, "GLP1-R" (retatrutide) and other coded GLP-1s; "laboratory research purposes only" rejected	FDA letter [11]
March 31, 2026 (April 7)	Mile High Compounds LLC	"GLP-1 SM", "GLP-2 TRZ", "GLP-3 RT" (retatrutide)	FDA letter [4]
Aug 24, 2026 (Sept 1)	Peptide Partners LLC	Semaglutide, tirzepatide, retatrutide; "for research use only" rejected	FDA letter [12]
Aug 24, 2026 (Sept 1)	Royal Peptides LLC	Retatrutide and other GLP-1s	FDA letter [5]
Aug 24, 2026 (Sept 1)	Peak Performance Peptides	Retatrutide and other GLP-1s	FDA letter [5]
Aug 24, 2026 (Sept 1)	NuScience Peptides LLC	Retatrutide, survodutide, mazdutide and others	FDA letter [5]
Aug 24, 2026 (Sept 1)	TXP Innovations dba Tex Peptides	Retatrutide and other GLP-1s	FDA letter [5]

Eli Lilly's August 2026 lawsuits

On Aug 12, 2026, Lilly announced six lawsuits against sellers it says falsely claimed their retatrutide was for "research use only" when it was meant for people ^[1]:

• Aesthetic Envy Cosmetic Centers (N.D. Cal.)
• Astra LLC dba Astra Peptides (W.D. Tex.)
• Legendary Peptides (E.D. Tex.)
• Striker Pharmacy (S.D. Tex.)
• Texas Peptides Inc. (W.D. Tex.)
• Lone Star Peptide Co. (S.D. Tex.)

Lilly also said it had referred more than 200 people and companies to FDA, the Justice Department, state attorneys general and licensing boards, and reported more than 14,000 websites, ads, posts and listings in over 100 countries ^[1]. Lawsuits are allegations until a court rules.

The risks, in plain terms

• Unknown contents and purity. No regulator checks what is in the vial ^[2]. Lilly is reported to have found samples with wrong doses, from none to overdose, and some with a different active ingredient such as insulin ^[13].
• Contamination. The same report says samples were likely made in non-sterile conditions ^[13]. Injecting a non-sterile product risks infection.
• Dose errors. FDA has reports of hospitalizations from GLP-1 dosing mistakes even with pharmacy-labeled compounded vials ^[2]. Unlabeled or mislabeled powders add another layer of guesswork.
• Serious reactions. Reports of serious side effects including liver failure have been linked to black-market retatrutide, per Lilly as reported by pharmaphorum ^[13].
• No recourse. If something goes wrong, there is no prescriber, pharmacy or label to turn to.

Legal options and what they cost

Approved GLP-1 options, self-pay prices checked Oct 17, 2026

Option	Price	How to get it	Source
Zepbound (tirzepatide) vial or KwikPen	$299 to $449 a month	Prescription sent to LillyDirect	[14]
Wegovy pen (semaglutide)	$349 a month; $199 for first 2 low-dose fills; 7.2 mg $399	Prescription to NovoCare or a pharmacy	[6]
Wegovy pill	$149 to $299 a month	Pharmacy, NovoCare or telehealth	[6]
Foundayo (orforglipron) pill	$149 to $299 a month	LillyDirect or pharmacy	[7]
Medicare GLP-1 Bridge	$50 a month copay	Eligible Part D members; Wegovy, Foundayo, Zepbound KwikPen	[15]
Commercial insurance with maker savings card	As little as $25	If your plan covers the drug	[16] [6]

For context on approved results: in SURMOUNT-5, people on tirzepatide lost an average of 20.2% of body weight at 72 weeks and people on semaglutide 13.7% ^[17]. Those are averages from the approved drugs, not a promise for any one person. Wegovy vs Zepbound has the details.